

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket 046124-5042-01

Application No. 10/785,320

Applicants: Tadimitsu Kishimoto *et al.*

Page 1 of 1

Filing Date: February 25, 2004

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	5,378,725	01/03/1995	Bonjouklian <i>et al.</i>	514	453	06/19/1993
2.	5,525,625	06/11/1996	Bridges <i>et al.</i>	514	456	01/24/1995

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
3.	EP 0897980	02/24/1999	EP	C12N	15/12	N/A
4.	WO 96/24598	08/15/1996	PCT	C07F	9/38	N/A

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

5.	Communication of Notice of Opposition for EP 99909307.3 filed by Eli Lilly and Company dated May 2, 2007.
6.	Communication of Notice of Opposition for EP 99909307.3 filed by Strawman Limited dated May 2, 2007.
7.	Bleul <i>et al.</i> (1997), The HIV coreceptors CXCR4 and CCRG are differentially expressed and regulated on human T lymphocytes, <i>Proc. Natl. Acad. Sci. USA</i> 94: 1925-1930.
8.	Donzella <i>et al.</i> (1998), AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor, <i>Nature Medicine</i> 4: 72-77.
9.	Doranz <i>et al.</i> (1997), A Small-molecule Inhibitor Directed against a Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor, <i>J. Exp. Med.</i> 8: 1395-1400.
10.	Eliceiri <i>et al.</i> (1998) Integrin $\alpha\beta 3$ Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis, <i>J. Cell. Biol.</i> 140: 1255-1263.
11.	Felszeghy <i>et al.</i> (2004) Dexamethasone Downregulates Chemokine Receptor CXCR4 and Exerts Neuroprotection against Hypoxia/Ischemia-Induced Brain Injury in Neonatal Rats, <i>Neuroimmunomodulation</i> 11: 404-413.
12.	Gupta <i>et al.</i> (1998), Chemokine Receptors in Human Endothelial Cells, <i>J. Biol Chem.</i> 273: 4282-4287.
13.	Hanahan <i>et al.</i> (1998), Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis, <i>Cell</i> 86: 352-364.
14.	Jackson <i>et al.</i> (1998) Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models, <i>J. Pharmacol. Exp. Therapeut.</i> 284: 687-692.
15.	Murakami <i>et al.</i> (1997) A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line-tropic HIV-1 Infection, <i>J. Exp. Med.</i> 186: 1389-1393.
16.	Oikawa <i>et al.</i> (1996) Potent inhibition of angiogenesis by wortmannin, a fungal metabolite, <i>European Journal of Pharmacology</i> 318: 93-96.
17.	Rafii <i>et al.</i> (1998) Regulation of Trafficking of Bone-Marrow Derived CD34+KDR+ Endothelial Progenitor Cells, Angiogenesis and Cancer, <i>Proceedings AACR Special Conference in Cancer Research.</i>
18.	Schols <i>et al.</i> (1997), Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4, <i>J. Exp. Med.</i> 186: 1383-1388.
19.	Stedmans Medical Dictionary, 26th Ed. (1995), 85, 1182, 1909.
20.	Strieter <i>et al.</i> (1995) Role of C-X-C chemokines as regulators of angiogenesis in lung cancer, <i>J. Leukocyte Biol.</i> 57: 752-761.
21.	Whalen (1990), Solid tumours and wounds: transformed cells misunderstood as injured tissue?, <i>The Lancet</i> 336: 1489-1492.

Examiner

Date Considered

9/20/07

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.